#USA #New York #Gross Law Firm #Cytokinetics #CYTK

Important Notice for Cytokinetics Shareholders

The Gross Law Firm has issued a key notice for shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Investors who acquired shares during the specified class period are encouraged to connect with the firm to discuss the possibility of being appointed as lead plaintiff in an emerging class action lawsuit.

Class Period and Allegations

The class period extends from December 27, 2023, to May 6, 2025. The allegations suggest that the defendants in this case made materially false and misleading statements concerning the New Drug Application (NDA) submission timeline and approval process for aficamten, a drug developed by Cytokinetics. Specifically, it has been claimed that the defendants suggested the company expected FDA approval for the NDA in the latter half of 2025, based on a designated PDUFA date of September 26, 2025, yet they failed to disclose significant risks that could impact the approval process due to the absence of a submitted Risk Evaluation and Mitigation Strategy (REMS).

On May 6, 2025, during a significant earnings call, it became clear that the company had held several pre-NDA meetings with the FDA about safety monitoring and risk mitigation but opted to submit the NDA without a REMS. This decision raised questions about the defendants' awareness of the potential requirements and illustrated a reckless disregard for the implications of omitting critical information concerning regulatory timelines. Consequently, investors suffered substantial losses once the true situation was disclosed, revealing the inflated stock prices as a result of these misleading statements.

Registration for Class Action

The deadline for shareholders to register as lead plaintiffs is set for November 17, 2025. Interested parties should not hesitate in registering their information. This class action aims to provide a platform for those affected by the misleading actions of the company to seek recovery for their losses. Upon registration, shareholders will also have access to portfolio monitoring software designed to keep them informed of the case's progress throughout its lifecycle.

To join the class action, shareholders are encouraged to complete a submission form available through Gross Law Firm’s website. There is no cost associated with registration, and being appointed as a lead plaintiff is not mandatory to partake in potential recovery.

Why Gross Law Firm?

The Gross Law Firm is recognized nationally in class action lawsuits and is dedicated to upholding the rights of investors facing losses due to misleading practices. The firm seeks to ensure corporate accountability by representing shareholders who have experienced financial harm due to a lack of transparency or deceptive statements made by the companies they invested in. If you have suffered losses due to the misleading information surrounding Cytokinetics, don't miss this chance to join your fellow investors in seeking justice.

Contact Information

Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Together, shareholders can hold Cytokinetics accountable and seek the recovery they deserve.